Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have been given an average recommendation of “Buy” by the nine analysts that are covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $19.80.

Several analysts recently issued reports on SGMO shares. Jefferies Group reaffirmed a “buy” rating and set a $18.00 price objective on shares of Sangamo Therapeutics in a report on Friday, October 13th. Piper Jaffray Companies raised shares of Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 price objective for the company in a report on Wednesday, November 15th. Zacks Investment Research raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Wednesday, November 15th. Wedbush reaffirmed a “hold” rating and set a $6.00 price objective on shares of Sangamo Therapeutics in a report on Wednesday, November 15th. Finally, BidaskClub raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, December 29th.

Sangamo Therapeutics (SGMO) traded down $0.55 during midday trading on Friday, hitting $17.31. 344,808 shares of the company traded hands, compared to its average volume of 1,380,000. The company has a current ratio of 5.64, a quick ratio of 5.64 and a debt-to-equity ratio of 0.02. The company has a market cap of $1,460.00, a P/E ratio of -25.08 and a beta of 3.15. Sangamo Therapeutics has a fifty-two week low of $3.25 and a fifty-two week high of $18.69.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.04. The business had revenue of $11.81 million during the quarter, compared to the consensus estimate of $10.37 million. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. Sangamo Therapeutics’s quarterly revenue was up 333.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.27) EPS. sell-side analysts anticipate that Sangamo Therapeutics will post -0.73 earnings per share for the current fiscal year.

In other news, VP Edward R. Conner sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $16.24, for a total transaction of $81,200.00. Following the completion of the transaction, the vice president now directly owns 5,000 shares of the company’s stock, valued at approximately $81,200. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Curt A. Herberts III sold 11,803 shares of the firm’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $18.00, for a total transaction of $212,454.00. Following the transaction, the vice president now directly owns 27,636 shares of the company’s stock, valued at $497,448. The disclosure for this sale can be found here. Over the last three months, insiders sold 53,433 shares of company stock valued at $894,146. Insiders own 5.50% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP bought a new position in shares of Sangamo Therapeutics during the 3rd quarter worth about $118,000. Amalgamated Bank bought a new position in shares of Sangamo Therapeutics during the 3rd quarter worth about $158,000. Blair William & Co. IL lifted its holdings in shares of Sangamo Therapeutics by 4.3% during the 2nd quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 500 shares during the period. Aperio Group LLC bought a new position in shares of Sangamo Therapeutics during the 2nd quarter worth about $108,000. Finally, Great West Life Assurance Co. Can lifted its holdings in shares of Sangamo Therapeutics by 150.3% during the 3rd quarter. Great West Life Assurance Co. Can now owns 12,767 shares of the biopharmaceutical company’s stock worth $182,000 after acquiring an additional 7,667 shares during the period. 64.33% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/05/sangamo-therapeutics-inc-sgmo-given-average-rating-of-buy-by-brokerages-2.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.